%0 Journal Article
%T TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-¦Â signaling
%A Jan C Brase
%A Marc Johannes
%A Heiko Mannsperger
%A Maria F£¿lth
%A Jennifer Metzger
%A Lukasz A Kacprzyk
%A Tatjana Andrasiuk
%A Stephan Gade
%A Michael Meister
%A H¨¹seyin Sirma
%A Guido Sauter
%A Ronald Simon
%A Thorsten Schlomm
%A Tim Bei£¿barth
%A Ulrike Korf
%A Ruprecht Kuner
%A Holger S¨¹ltmann
%J BMC Cancer
%D 2011
%I BioMed Central
%R 10.1186/1471-2407-11-507
%X We studied large-scale gene expression profiles in 47 prostate tumor tissue samples and in 48 normal prostate tissue samples taken from the non-suspect area of clinical low-risk tumors using Affymetrix GeneChip Exon 1.0 ST microarrays.Comparison of gene expression levels among TMPRSS2-ERG fusion-positive and negative tumors as well as benign samples demonstrated a distinct transcriptional program induced by the gene fusion event. Well-known biomarkers for prostate cancer detection like CRISP3 were found to be associated with the gene fusion status. WNT and TGF-¦Â/BMP signaling pathways were significantly associated with genes upregulated in TMPRSS2-ERG fusion-positive tumors.The TMPRSS2-ERG gene fusion results in the modulation of transcriptional patterns and cellular pathways with potential consequences for prostate cancer progression. Well-known biomarkers for prostate cancer detection were found to be associated with the gene fusion. Our results suggest that the fusion status should be considered in retrospective and future studies to assess biomarkers for prostate cancer detection, progression and targeted therapy.Prostate cancer is the most frequently diagnosed malignancy and still one of the leading causes of cancer related death in men [1]. Since the discovery of a recurrent gene fusion between the androgen responsive gene TMPRSS2 (transmembrane protease, serine 2) and ERG (v-ets erythroblastosis virus E26 homolog (avian)) on chromosome 21 [2], prostate cancers are molecularly divided into "fusion-positive" and "fusion-negative" cancers. Although the TMPRSS2-ERG fusion is a critical early and common event in prostate cancer development and progression [3,4], the clinical implications of the fusion are controversial [5-9] and the functional consequences are unclear.After the rearrangement, ERG expression is driven by the androgen-responsive promoter of TMPRSS2, resulting in a significant upregulation of the transcription factor ERG [2,10]. Initial in vitro expe
%K Prostate cancer
%K TMPRSS2-ERG
%K Gene expression profiling
%U http://www.biomedcentral.com/1471-2407/11/507